2023
Single-Dose Psilocybin Treatment for Major Depressive Disorder
Raison C, Sanacora G, Woolley J, Heinzerling K, Dunlop B, Brown R, Kakar R, Hassman M, Trivedi R, Robison R, Gukasyan N, Nayak S, Hu X, O’Donnell K, Kelmendi B, Sloshower J, Penn A, Bradley E, Kelly D, Mletzko T, Nicholas C, Hutson P, Tarpley G, Utzinger M, Lenoch K, Warchol K, Gapasin T, Davis M, Nelson-Douthit C, Wilson S, Brown C, Linton W, Johnson M, Ross S, Griffiths R. Single-Dose Psilocybin Treatment for Major Depressive Disorder. JAMA 2023, 330: 843-853. PMID: 37651119, PMCID: PMC10472268, DOI: 10.1001/jama.2023.14530.Peer-Reviewed Original ResearchConceptsMajor depressive disorderSheehan Disability Scale scoresAdverse eventsDisability scale scorePsilocybin treatmentDay 43Scale scoreSecondary outcomesSingle doseDepressive disorderExclusion criteriaPsychological supportMontgomery-Asberg Depression Rating Scale scoreSerious treatment-emergent adverse eventsDay 8Key secondary outcome measuresTreatment-emergent adverse eventsDepression Rating Scale scoresActive substance use disorderFifth Edition diagnosisIdentical-appearing capsulesOverall adverse eventsPhase 2 trialSerious adverse eventsSevere adverse events
2020
Effectiveness of enhanced cognitive behavior therapy for bulimia nervosa in Japan: a randomized controlled trial protocol
Ohara C, Sekiguchi A, Takakura S, Endo Y, Tamura N, Kikuchi H, Maruo K, Sugawara N, Hatano K, Kawanishi H, Funaba M, Sugawara A, Nohara N, Kawai K, Fukudo S, Sudo N, Cooper Z, Yoshiuchi K, Ando T. Effectiveness of enhanced cognitive behavior therapy for bulimia nervosa in Japan: a randomized controlled trial protocol. BioPsychoSocial Medicine 2020, 14: 2. PMID: 32123540, PMCID: PMC7041176, DOI: 10.1186/s13030-020-0174-z.Peer-Reviewed Original ResearchCognitive behavior therapyBody mass indexStart of treatmentBulimia nervosaBehavior therapyEffectiveness of CBTTreatment of BNDiagnosis of BNFifth Edition diagnosisWeeks of treatmentEnd of treatmentYears of ageDSM-5 criteriaSecondary outcomesMulticenter RCTPrimary outcomeMass indexFirst RCTRoutine treatmentTAU groupTrial protocolAdult outpatientsEdition diagnosisHigh prevalenceIntervention sites
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply